Welcome to our dedicated page for Edwards Lifesciences SEC filings (Ticker: EW), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Edwards Lifesciences Corporation (NYSE: EW) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as a structural heart medical device manufacturer. These filings, sourced from the SEC’s EDGAR system, include current reports on material events, earnings announcements, capital markets activity and other items relevant to shareholders and analysts.
Edwards Lifesciences uses Form 8‑K to report developments such as quarterly financial results, financial guidance updates, leadership transitions, accelerated share repurchase agreements and legal or regulatory matters. Recent 8‑K filings, for example, describe third‑quarter financial results, a planned chief financial officer transition, an accelerated share repurchase agreement and legal proceedings related to the Federal Trade Commission’s successful motion to block the proposed acquisition of JenaValve Technology.
In addition to current reports, investors typically review Edwards’ annual reports on Form 10‑K and quarterly reports on Form 10‑Q, which provide detailed information on its structural heart portfolio, risk factors, research and development spending, and segment performance across transcatheter aortic valve replacement, transcatheter mitral and tricuspid therapies and surgical heart valves. Proxy statements on Schedule 14A and beneficial ownership or insider trading reports on Forms 3, 4 and 5 offer further insight into governance and executive equity activity.
Stock Titan enhances these filings with AI‑powered summaries that explain key points in accessible language, highlight important changes from prior periods and help readers interpret complex sections. Real‑time updates ensure that new Edwards Lifesciences filings appear promptly, while AI‑generated overviews of 10‑K, 10‑Q and Form 4 documents can assist users in quickly understanding the implications of lengthy disclosures and insider transactions without replacing their own review of the original filings.
Edwards Lifesciences (EW) furnished a press release announcing its financial results for the third quarter of 2025. The disclosure was made via Form 8-K under Item 2.02.
The press release is included as Exhibit 99.1 and the information is being furnished, not deemed filed, under the Exchange Act.
Edwards Lifesciences (EW) furnished a press release announcing its financial results for the third quarter of 2025. The disclosure was made via Form 8-K under Item 2.02.
The press release is included as Exhibit 99.1 and the information is being furnished, not deemed filed, under the Exchange Act.
BlackRock, Inc. filed a Schedule 13G/A reporting beneficial ownership of 44,267,376 shares (7.5%) of Edwards Lifesciences common stock as of 09/30/2025.
BlackRock reports sole voting power over 40,035,206 shares and sole dispositive power over 44,267,376 shares, with no shared voting or dispositive power. The filer is classified as a HC (parent holding company) and certifies the securities were acquired and are held in the ordinary course, not for the purpose of changing or influencing control.
Edwards Lifesciences (EW) reported a Form 144 notice indicating that Larry L. Wood plans to sell 8,950 shares of common stock. The filing lists an aggregate market value of 653,522.00 and an approximate sale date of 10/16/2025. The broker is Charles Schwab & Co., Inc., and the shares are listed on the NYSE.
The shares to be sold were acquired on 10/16/2025 through an employee stock option exercise via a broker payment for cashless exercise. The filing also notes a prior sale in the past three months: 8,950 shares on 08/18/2025 for gross proceeds of 698,679.00. Shares outstanding are listed as 587,100,000; this is a baseline figure, not the amount being sold.
Andrew M. Dahl, SVP and Corporate Controller of Edwards Lifesciences (EW), reported a sale of 262 shares of common stock on 09/13/2025 at a price of $77.57 per share. After the reported transaction, the filing shows beneficial ownership of 7,926.9331 shares. The form notes this filing reflects changes in beneficial ownership only and includes a quarterly acquisition under the issuer's Employee Stock Purchase Plan.
Andrew M. Dahl, SVP and Corporate Controller of Edwards Lifesciences (EW), reported a sale of 262 shares of common stock on 09/13/2025 at a price of $77.57 per share. After the reported transaction, the filing shows beneficial ownership of 7,926.9331 shares. The form notes this filing reflects changes in beneficial ownership only and includes a quarterly acquisition under the issuer's Employee Stock Purchase Plan.
Daveen Chopra, an officer (CVP, TMTT & Surgical) of Edwards Lifesciences Corporation (EW), received 3,205 restricted stock units (RSUs) on 09/11/2025 under the companys Long-Term Stock Incentive Compensation Program at an effective price of $0.0000. The RSUs are scheduled to vest in four equal annual installments beginning one year after the grant date. After this reported grant, the filing shows 34,201 shares beneficially owned by the reporting person. The Form 4 was signed by an attorney-in-fact and filed on 09/15/2025. The form notes it reflects changes in beneficial ownership only.
Daveen Chopra, an officer (CVP, TMTT & Surgical) of Edwards Lifesciences Corporation (EW), received 3,205 restricted stock units (RSUs) on 09/11/2025 under the companys Long-Term Stock Incentive Compensation Program at an effective price of $0.0000. The RSUs are scheduled to vest in four equal annual installments beginning one year after the grant date. After this reported grant, the filing shows 34,201 shares beneficially owned by the reporting person. The Form 4 was signed by an attorney-in-fact and filed on 09/15/2025. The form notes it reflects changes in beneficial ownership only.
Edwards Lifesciences director and officer Wayne Markowitz reported two transactions in September 2025 affecting his holdings in Edwards Lifesciences (EW). On 09/11/2025 he was granted 6,410 restricted stock units (RSUs) under the companys Long-Term Stock Incentive Compensation Program; those RSUs vest in four equal annual installments beginning one year after the grant date. On 09/14/2025 he sold 650 shares of common stock at a price of $77.57 per share. After these transactions he beneficially owns 18,145.8708 shares directly. The Form 4 notes the RSU grant and also references quarterly ESPP share acquisitions; no derivative transactions were reported.
Edwards Lifesciences director and officer Wayne Markowitz reported two transactions in September 2025 affecting his holdings in Edwards Lifesciences (EW). On 09/11/2025 he was granted 6,410 restricted stock units (RSUs) under the companys Long-Term Stock Incentive Compensation Program; those RSUs vest in four equal annual installments beginning one year after the grant date. On 09/14/2025 he sold 650 shares of common stock at a price of $77.57 per share. After these transactions he beneficially owns 18,145.8708 shares directly. The Form 4 notes the RSU grant and also references quarterly ESPP share acquisitions; no derivative transactions were reported.
Edwards Lifesciences (EW) insider sale disclosed on Form 4. Reporting person Daveen Chopra, listed as an officer (CVP, TMTT), sold 2,500 shares of Edwards Lifesciences common stock on 08/25/2025 at a weighted average price of $81.946 per share. After the sale the filing reports 30,996 shares beneficially owned by the reporting person, held directly. The filing states the reported sale was executed in multiple trades at prices ranging from $81.9401 to $81.9500 and that the weighted average price is provided; the filer offers to supply detailed trade-by-trade information upon request. The form notes it reflects changes in beneficial ownership only and does not list other securities the reporting person may own.
Edwards Lifesciences (EW) Form 144 notifies of a proposed sale of 2,500 shares of common stock through Charles Schwab & Co., Inc. with an aggregate market value of $204,865.00. The sale is scheduled to occur approximately on 08/25/2025 on the NYSE. The shares being offered were acquired as equity compensation: 657 shares from RSU/PSU on 05/08/2022, 1,671 shares from a restricted stock lapse on 05/17/2022, and 172 shares from a restricted stock lapse on 05/03/2023. No securities were reported sold in the past three months on this form. The filer certifies compliance with the Rule 144 representation regarding material nonpublic information.
Edwards Lifesciences Corporation reported that on August 19, 2025 it issued a press release announcing that the company entered into an accelerated share repurchase agreement. This type of agreement typically allows a company to buy back a significant number of its shares more quickly than through open-market repurchases, which can affect earnings per share and overall capital structure.
The press release describing the accelerated share repurchase is included as Exhibit 99.1 and is incorporated by reference, meaning the detailed terms and conditions are contained in that accompanying document rather than in this report.
Edwards Lifesciences (EW) insider activity: On 08/18/2025, Larry L. Wood, Global President TAVR & Surg, reported option exercise and related open-market sales under a Rule 10b5-1 plan. He acquired 8,950 shares via exercise of employee stock options at an exercise price of $59.2567 and then sold 8,950 shares in multiple trades at a weighted average sale price of $78.0647.
Following these transactions, the filing shows Mr. Wood beneficially owns 215,850.3913 shares after the acquisition and 206,900.3913 after the sale; an additional 148.1703 shares are held indirectly in a 401(k). The 10b5-1 plan was adopted on February 27, 2025, and the report is signed by an attorney-in-fact on 08/18/2025.